Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2005
05/12/2005WO2005042476A2 Prodrugs of diaryl-2-(5h)-furanone cyclooxygenase-2 inhibitors
05/12/2005WO2005042464A1 Androgen receptor modulators
05/12/2005WO2005042422A2 Optical fiber with low pmd and method of making it by spinning
05/12/2005WO2005042101A1 Composition and dosage form for sustained effect of levodopa
05/12/2005WO2005042072A1 Implantable infusion pump for the administration of intrathecal gabapentin for treatment of pain
05/12/2005WO2005042060A2 Method and composition comprising pyruvate, inosine, adenine, phosphate and an aziridino compound for treating a biological sample
05/12/2005WO2005042032A1 Methods for treating multiple sclerosis
05/12/2005WO2005042030A1 Treatment of proliferative diseases using an antisense iap oligomer and chemotherapeutic agent
05/12/2005WO2005042022A2 Combination of an activator of solubleguanylate cyclase and an angiotensin ii receptor antagonist
05/12/2005WO2005042021A2 Pharmaceutical composition, containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha-reductase inhibitor
05/12/2005WO2005042020A2 Combinations for hcv treatment
05/12/2005WO2005042015A1 Pharmaceutical anti-herpetic composition, method for producing a dosage form based thereon and method for the use thereof
05/12/2005WO2005042002A2 Treatment of rhematoid arthritis with flip antagonists
05/12/2005WO2005041999A1 Composition to enhance joint function and repair
05/12/2005WO2005041997A1 Methods and compositions comprising ilex
05/12/2005WO2005041994A1 Use of prickly pear (opuntia) plant parts and/or extracts for the treatment of depressions
05/12/2005WO2005041989A1 Topical agent and use of potassium antimonyl tartrate for preparing said agent
05/12/2005WO2005041988A1 Method and composition for pain amelioration
05/12/2005WO2005041987A1 Polymerizable emulsions for tissue engineering
05/12/2005WO2005041986A2 Use of biocompatible polymers for the preparation of a composition or a medical device
05/12/2005WO2005041985A1 Polysaccharides of plants belonging to panax having effect on treatment and prevention of obesity
05/12/2005WO2005041984A1 Compositions and treatments for envelope virus infections
05/12/2005WO2005041983A1 Medicament comprising a reducing alkyl-sugar monomer for the treatment of inflammatory disorders
05/12/2005WO2005041982A1 Combination therapy of peptide vaccination and estramustine treatment
05/12/2005WO2005041981A1 Combination therapy of peptide vaccination and estramustine treatment
05/12/2005WO2005041980A1 Soft steroid compositions for use in dry powder inhalers
05/12/2005WO2005041979A1 Modulation of microglial by nicotinic medications
05/12/2005WO2005041978A1 Neuroprotection with beta-lactam compounds
05/12/2005WO2005041977A2 Process for producing injectable gabapentin compositions
05/12/2005WO2005041975A1 Use of bh4 for the treatment of respiratory diseases
05/12/2005WO2005041974A1 Agents for weight reduction
05/12/2005WO2005041973A1 Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
05/12/2005WO2005041972A1 Phosphodiesterase 9 inhibition as treatment for obesity-related conditions
05/12/2005WO2005041969A1 Pharmaceutical product comprising a beta-2 adrenergic agonist and an h1-receptor antagonist
05/12/2005WO2005041968A2 Once-a-day, oral, controlled-release, oxycodone dosage forms
05/12/2005WO2005041967A1 Transdermal preparations and method for relieving side effects in pergolide therapy
05/12/2005WO2005041966A1 Treatment of parkinson's disease using apomorphine in combination with an apomorphine prodrug
05/12/2005WO2005041965A1 Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
05/12/2005WO2005041964A1 The use of ifenprodril in the treatment of pain
05/12/2005WO2005041963A1 The use of non-opiates for the potentation of opiates
05/12/2005WO2005041962A1 Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
05/12/2005WO2005041961A1 Imidazo [1,2-a] pyridine derivatives for the treatment of silent gastro-esophageal reflux
05/12/2005WO2005041960A2 Neuromuscular blocking agents and antagonists thereof
05/12/2005WO2005041959A1 Phenoxyacetic acids derivatives useful as peroxisome proliferator-activated receptor (ppar) dual agonists
05/12/2005WO2005041958A1 Novel compositions
05/12/2005WO2005041957A1 Oxindole derivatives and their use as phosphodiesterase type 2 inhibitors
05/12/2005WO2005041956A1 Pharmaceutical compositions based on idazoxan salt or one of the polymorphs thereof
05/12/2005WO2005041955A1 Methods for treating non-microbial inflammatory skin conditions
05/12/2005WO2005041954A1 Indirubin-type compounds, compositions, and methods for their use
05/12/2005WO2005041953A1 Bisindolyl maleimides useful for treating prostate cancer and akt-mediated diseases
05/12/2005WO2005041952A1 Pharmaceutical composition exhibiting a cerebral vasodilatation and nootropic activity
05/12/2005WO2005041951A2 Rhodanine derivatives for use as antiviral agents
05/12/2005WO2005041950A1 Ectoparasiticidal formulations of spinosyns and azole pesticides
05/12/2005WO2005041949A1 Composition for the treatment of dysfunctional energy metabolism syndrome
05/12/2005WO2005041948A1 Punctual stimulation therapy
05/12/2005WO2005041947A1 Intrathecal gabapentin for treatment of epilepsy
05/12/2005WO2005041945A1 Composition containing reduced coenzyme q
05/12/2005WO2005041944A2 Methods and compositions for promoting axon regeneration and cell replacement therapy
05/12/2005WO2005041943A1 Transdermal pharmaceutical spray formulations comprising a vp/va copolymer and a non-aqueous vehicle
05/12/2005WO2005041941A2 Valsartan containing formulation
05/12/2005WO2005041940A1 Stable formulations of ace inhibitors and methods for preparation thereof
05/12/2005WO2005041939A1 Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
05/12/2005WO2005041938A1 Non-effervescent form of sodium naproxen comprising i.a. sodium hydrogen carbonate
05/12/2005WO2005041937A2 Controlled release sterile injectable aripiprazole formulation and method
05/12/2005WO2005041935A1 Pharmaceutical formulations containing quetiapine
05/12/2005WO2005041931A2 Pharmaceutical aerosol compositions
05/12/2005WO2005041929A1 Pharmaceutical compositions with synchronized solubilizer release
05/12/2005WO2005041928A1 Compositions and dosage forms for ehnanced absorption of iron
05/12/2005WO2005041927A1 Compositions and dosage forms for enhanced absorption of gabapentin and pregabalin
05/12/2005WO2005041926A1 Compositions and dosage forms for enhanced absorption of 3-amino-n-butyl-phosphinic acid
05/12/2005WO2005041925A2 Compositions and dosage forms for enhanced absorption
05/12/2005WO2005041924A2 Administration of levodopa and carbidopa
05/12/2005WO2005041923A1 Compositions and dosage forms for enhanced absorption of metformin
05/12/2005WO2005041922A2 Composition
05/12/2005WO2005041921A2 Dry powder compositions for inhalation therapy comprising calcium stearate, medical devices therefor
05/12/2005WO2005041920A2 Pharmaceutical licofelone formulation
05/12/2005WO2005041919A2 Medicamentously targeted local lipolysis
05/12/2005WO2005041906A1 Use of citric acid and low concentrations of alpha-hydroxy acids for superficial skin treatment
05/12/2005WO2005041904A2 Inhibitors of coronavirus protease and methods of use thereof
05/12/2005WO2005041902A2 Anion-binding polymers and uses thereof
05/12/2005WO2005041900A2 Polyamine polymers
05/12/2005WO2005041894A2 Compositions and methods for treating, preventing, reversing and inhibiting pain
05/12/2005WO2005041892A2 Purine receptor inhibition as a therapeutic strategy in spinal cord and brain
05/12/2005WO2005041889A2 Personal care composition containing a detersive surfactant, an antidandruff component, and ketoamide surfactants
05/12/2005WO2005041888A2 Pyrimidin-4-one compounds, compositions and methods
05/12/2005WO2005041881A2 Taxoid-fatty acid conjugates and pharmaceutical compositions thereof
05/12/2005WO2005041879A2 COMBINATIONS COMPRISING AN Hsp90 INHIBITOR AND A PHOPHODIESTERASE INHIBITOR FOR TREATING OR PREVENTING NEOPLASIA
05/12/2005WO2005041878A2 Compositions and methods for increasing hdl and hdl-2b levels
05/12/2005WO2005041875A2 Dopamine-, norepinephrine- and serotonin- transporter- selective heterocyclic compounds and their therapeutic applications
05/12/2005WO2005041874A2 Method and antisense composition for selective inhibition of hiv infection in hematopoietic cells
05/12/2005WO2005041870A2 Composition and method for the treatment of eye disease
05/12/2005WO2005041869A2 Process for co-spray drying agents with dry silicified mcc
05/12/2005WO2005041867A2 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3’(1h-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrozol-3-one choline
05/12/2005WO2005041861A2 Anhydrous silver dihydrogen citrate compositions
05/12/2005WO2005041858A2 Mucin production inhibitor
05/12/2005WO2005041856A2 Use of 2-thia-dibenzo[e, h]azulenes for the treatment and prevention of central nervous system diseases and disorders
05/12/2005WO2005041855A2 Pharmaceutical formulation containing an ltb4 antagonist, method for the production thereof, and use thereof
05/12/2005WO2005041853A2 Antibacterial and/or antiprotozoal nitroimidazole derivative compounds with urease inhibitor activity, process for preparing these compounds and use in pharmaceutical compositions and medicines.
05/12/2005WO2005041691A1 Use of hydroxyoleic acid and related compounds as functional food additives
05/12/2005WO2005041662A1 Method for treating collagenous tissue
1 ... 4691 4692 4693 4694 4695 4696 4697 4698 4699 4700 4701 4702 4703 4704 4705 4706 4707 4708 4709 4710 4711 ... 7860